Magrolimab was also noted to have activity in TP53-mutated MDS cases (n = 25), with a median CR duration of 7.6 months, median PFS of 11.0 months, and median OS of 18.7 months for patients who underwent allo-HSCT (n = 4), compared to 12.1 months for those who did not undergo allo-HSCT [74]. This evidence concerns the gene TP53 and myelodysplastic syndrome.